access

News

Pharma accuses UK of ‘mixed messages’ on rebate schemes

The pharma industry and the UK government may have reached an accord on the voluntary scheme of rebates used to limit rises in medicines spending in the UK, but the altern

Sales & Marketing

Improving access to brand planning tools through modular off...

Daniel Kohlstaedt, managing director and founder of PurpleLeaf Strategy, explores the ways brand leaders can leverage specific brand planning tools as an alternative to full suite platforms

News

Federal appeals court backs limits on abortion pill

A federal appeals court in the US has partially backed a lower court ruling that would restrict access to the medical abortion pill mifepristone, with the dispute now like

R&D

Collaborative perseverance to bring change to medicine acces...

Recently, pharmaphorum web editor Nicole Raleigh spoke with Herbert Altmann, head of commercialisation and access solutions Europe at PharmaLex, and Casper Paardekooper, partner at Vintura.

News

ABPI slams UK government consultation on drug levy

For all the UK government’s rhetoric on supporting the life sciences industry, it seems destined to alienate the very sector it is trying to court.

News

Uptake of Leqembi for Alzheimer’s may be slow

Full FDA approval of Eisai and Biogen’s Alzheimer’s disease therapy Leqembi may have unlocked the door to a broader rollout of the drug and potentially blockbuster sales,

Pharma accuses UK of ‘mixed messages’ on rebate schemes

Improving access to brand planning tools through modular off...

Federal appeals court backs limits on abortion pill

Collaborative perseverance to bring change to medicine acces...

ABPI slams UK government consultation on drug levy

Uptake of Leqembi for Alzheimer’s may be slow

Gilead, MSD share data on once-weekly oral HIV treatment

Discover a new era of healthcare panel engagement: Grounded ...

access

Editor's Picks